Oppenheimer assumed coverage on shares of Cara Therapeutics (NASDAQ:TVRD - Free Report) in a research report released on Wednesday, MarketBeat reports. The firm issued an outperform rating and a $65.00 price target on the stock.
Separately, Wall Street Zen upgraded Cara Therapeutics to a "hold" rating in a research note on Saturday.
Get Our Latest Analysis on Cara Therapeutics
Cara Therapeutics Trading Up 14.8%
NASDAQ TVRD traded up $4.30 on Wednesday, reaching $33.39. The stock had a trading volume of 74,552 shares, compared to its average volume of 20,121. Cara Therapeutics has a 12-month low of $8.13 and a 12-month high of $34.31.
About Cara Therapeutics
(
Get Free Report)
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Recommended Stories
Before you consider Cara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cara Therapeutics wasn't on the list.
While Cara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
